SWOT Analysis

Strength:
- GLP-1 receptor agonists help in weight reduction and control blood sugar levels effectively in patients with type 2 diabetes. They are considered more effective than other oral anti-diabetic drugs.
- Recent approval of once-weekly GLP-1 receptor agonists has improved patient adherence and compliance to treatment. Their longer duration of action provides sustained glycemic control.
- Strong pipeline of GLP-1 receptor agonists in late stages of clinical development will drive market revenues if approved.

Weakness:
- GLP-1 receptor agonists are administered via injections which many patients dislike due to pain and discomfort associated with needle sticks.
- Their high cost compared to generic alternatives like metformin and sulfonylureas restricts their widespread adoption.

Opportunity:
- Increasing prevalence of type 2 diabetes worldwide due to obesity, sedentary lifestyle and junk food consumption is driving demand for improved diabetes management therapies.
- Emerging economies like China, India and Latin America with huge diabetic populations present lucrative markets for launch of affordable GLP-1 receptor agonists.

Threats:
- Patent expiries of major blockbuster GLP-1 receptor agonists will enable market entry of cheaper biosimilars, resulting in more treatment affordability but lower prices.
- Development of novel anti-diabetic drug classes like SGLT-2 inhibitors pose competition to GLP-1 receptor agonists in gaining more patients and clinical usage.

Key Takeaways

The Global GLP-1 Receptor Agonist Market Size is expected to witness high growth.

Regional analysis: North America currently dominates the market and is expected to retain its position throughout the forecast period owing to growing diabetic population, higher healthcare awareness and rapid adoption of novel treatment options. The Asia Pacific market is anticipated to grow at the fastest pace during the forecast period, driven by economic development, expanding medical infrastructure and government initiatives to improve access to diabetes care in populous nations like China and India.

Key players operating in the GLP-1 receptor agonist market are Eli Lilly, Novo Nordisk, AstraZeneca, Sanofi, GlaxoSmithKline, and others.

Explore more information on this topic, Please visit-  
https://www.rapidwebwire.com/glp-1-receptor-agonist-market-size-and-share-analysis-growth-trends-and-forecasts-2/